Funding
2024 investment disclosed October 2026 · Healthtech

XEIA discloses its 2024 investment in Coherence Neuro

The investor first backed the cancer neurotechnology company in 2024 and subsequently joined its seed and Series A rounds.

By RoundOS Funding desk

XEIA Venture Partners disclosed on October 21, 2026 that it first invested in Coherence Neuro in 2024. The investor did not disclose the size or terms of that initial investment.

Coherence develops implantable neurotechnology to monitor and potentially treat cancer through electrical stimulation. XEIA subsequently invested in its 2025 seed round and the $45 million Series A announced in October 2026, extending its backing across three financing events.

Funding history

2024 investment disclosed October 2026 · This roundUndisclosed
ARIA opportunity seed research grant£500KSeed$10MSPARCLE research grant project disclosed July 2025£720.3KInnovate UK Smart grant£346.4KDecember 2022 pre-seed announced March 2023£1.9MCancer Tech Accelerator grant disclosed August 2022£70K

Sources

  1. XEIA discloses original2024Coherenceinvestmentxeiavp.com · Oct 21, 2026

Similar rounds

All Healthtech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related